The Takimoto laboratory focuses on the mechanism of cardiac hypertrophy and remodeling. We are currently investigating how cGMP-dependent protein kinase (PKG) targets intracellular signaling cascades, ameliorating cardiac mal-adaptive remodeling.
cGMP signaling has recently been recognized as “brake” against various cardiac pathologic stress, and the NIH-sponsored multi-center clinical trial is now testing cGMP-specific PDE5 inhibitor in (non-systolic) heart failure patients. Understanding the molecular mechanism of cGMP mediated cardio-protection is taking on more importance.
The unique combination of sophisticated cardiac physiology study in vivo (PV loop analysis in mice) and molecular techniques enable us to better assess the complicated patho-physiology of cardiac hypertrophy and failure.